Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis

Infection and Immunity

Volumn 71, Issue 2, 2003, Pages 656-662

  Cunnion, K M ^a,b   Zhang, H M ^a   Frank, M M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT RECEPTOR; MEMBRANE RECEPTOR;

ARTICLE; BACTEREMIA; BACTERIAL MEMBRANE; COMPLEMENT FIXATION; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; NEUTROPHIL; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SURVIVAL;

ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; COMPLEMENT C3; ERYTHROCYTES; HUMANS; NEUTROPHILS; OPSONIN PROTEINS; PHAGOCYTOSIS; RECEPTORS, COMPLEMENT; RECEPTORS, COMPLEMENT 3B; STAPHYLOCOCCUS AUREUS;

EID: 0037306528     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.71.2.656-662.2003     Document Type: Article

References (27)

1. Albus, A., R. D. Arbeit, and J. C. Lee. 1991. Virulence of Staphylococcus aureus mutants altered in type 5 capsule expression. Infect. Immun. 59:1008-1014.
2. Baddour, L. M., C. Lowrance, A. Albus, J. H. Lowrance, S. K. Anderson, and J. C. Lee. 1992. Staphylococcus aureus microcapsule expression attenuates bacterial virulence in a rat model of experimental endocarditis. J. Infect. Dis. 165:749-753.
3. Brown, E. J., S. W. Hosea, C. H. Hammer, C. G. Burch, and M. M. Frank. 1982. A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J. Clin. Investig. 69:85-98.
4. Centers for Disease Control and Prevention. 1996. National Nosocomial Infection Surveillance System report: data summary from October 1986 to April 1996. U.S. Department of Health and Human Services, Atlanta, Ga.
5. Cunnion, K. M., J. C. Lee, and M. M. Frank. 2001. Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect. Immun. 69:6796-6803.
6. Fattom, A., R. Schneerson, D. C. Watson, W. W. Karakawa, D. Fitzgerald. I. Pastan, X. Li, J. Shiloach, D. A. Bryla, and J. B. Robbins. 1993. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsule polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect. Immun. 61:1023-1032.
7. Fattom, A. I., J. Sarwar, A. Oritz, and R. Naso. 1996. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun. 64:1659-1665.
8. Frank, M. M. 1995. The complement system, p. 331-353. In M. M. Frank (ed.), Samter's immunologic diseases. Little, Brown, & Co., Boston, Mass.
9. Fries, L. F., T. A. Gaither, C. H. Hammer, and M. M. Frank. 1984. C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J. Exp. Med. 160:1640-1655.
10. Gaither, T. A., C. H. Hammer, and M. M. Frank. 1979. Studies of the molecular mechanisms of C3b inactivation and a simplified assay of β1H and the C3b inactivator (C3bINA). J. Immunol. 123:1195-1204.
11. Goetz, A., K. Posey, J. Flemming, S. Jacobs, L. Boody, M. M. Wagener, and R. R. Muder. 1999. Methicillin-resistant Staphylococcus aureus in the community: a hospital-based study. Infect. Control Hosp. Epidemiol. 20:689-691.
12. Horowitz, M. A., and S. C. Silverstein. 1980. Influence of Escherichia coli capsule on the complement fixation and on phagocytosis and killing by human phagocytes. J. Clin. Investig. 65:82-94.
13. Karakawa, W. W., A. Sutton, R. Schneerson, A. Karpas, and W. F. Vann. 1988. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect. Immun. 56:1090-1095.
14. Lee, J. C., J.-S. Park, S. E. Shepherd, V. Carey, and A. Fattom. 1997. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect. Immun. 65:4146-4151.
15. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
16. Na'was, T., A. Hawwari, E. Hendrix, J. Hebden, R. Edelman, M. Martin, W. Campbell, R. Naso, and A. Fattom. 1998. Phenotypic and genotypic characterization of nosocomial Staphylococcus aureus isolates from trauma patients. J. Clin. Microbiol. 36:414-420.
17. Nilsson, I. M., J. C. Lee, T. Bremell, C. Ryden, and A. Tarkowski. 1997. The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis. Infect. Immun. 65:4216-4221.
18. Portoles, M., K. B. Kiser, N. Bhasin, K. H. N. Chan, and L. C. Lee. 2001. Staphylococcus aureus Cap50 has UDP-ManNAc dehydrogenase activity and is essential for capsule expression. Infect. Immun. 69:917-923.
19. Rubin, R. J., C. A. Harrington, A. Poon, K. Dietrich, J. A. Greene, and A. Moiduddin. 1999. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg. Infect. Dis. 5:9-17.
20. Shinefield, H., S. Black, A. Fattom, G, Horwith, S. Rasgon, J. Ordonez, H. Yeoh, D. Law, J. B. Robbins, R. Schneerson, L. Muenz, S. Fuller, J. Johnson, B. Fireman, H. Alcorn, and R. Naso. 2002. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346: 491-496.
21. Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, F. C. Tenover, M. J. Zervos, J. D. Band, E. White, and R. W. Jarvis. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340:493-501.
22. Sompolinsky, D., Z. Samra, W. W. Karakawa, W. F. Vann, R. Schneerson, and Z. Malik. 1985. Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types. J. Clin. Microbiol, 22:828-834.
23. Thakker, M., J. S. Park, V. Carey, and J. C. Lee. 1998. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect. Immun. 66:5183-5189.
24. Verbrugh, H. A., R. Peters, M. Rozenberg-Arska, P. K. Peterson, and J. Verhoef. 1981. Antibodies to cell wall peptidoglycan of Staphylococcus aureus in patients with serious staphylococcal infections. J. Infect. Dis. 144:1-9.
25. Welch, P. G., A. Fattom, J. Moore, R. Schneerson, J. Shiloach, D. A. Bryla, X. Li, and J. B. Robbins. 1995. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. J. Am. Soc. Nephrol. 7:247-253.
26. Wergeland, A. I., L. R. Haaheim, O. B. Natas, F. Wesenberg, and P. Oeding. 1989. Antibodies to staphylococcal peptidoglycan and its peptide epitopes, teichoic acid, and lipoteichoic acid in sera from blood donors and patients with staphylococcal infections. J. Clin. Microbiol. 27:1286-1291
27. Xu, S., R. D. Arbeit, and J. C. Lee. 1992. Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect. Immun. 60:1358-1362.